Amneal Submits Abbreviated New Drug Applications To U.S. FDA For Three Key Complex Generics
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals has submitted Abbreviated New Drug Applications (ANDAs) to the U.S. FDA for three complex generics. The drugs include Albuterol sulfate inhalation, Bimatoprost ophthalmic solution, and Propofol emulsion, with U.S. IQVIA sales of $814 million, $779 million, and $311 million respectively.
July 26, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amneal's submission of ANDAs for three complex generics could potentially boost its revenue, given the significant sales of these drugs in the U.S.
The submission of ANDAs for these drugs indicates Amneal's intent to manufacture and sell these generics in the U.S. market. Given the significant sales of these drugs, this could potentially lead to increased revenue for Amneal, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100